Physician profile
Amanda Lee
NPI 1194260067
$1,913.91
in general payments reported to CMS, 2019-2025
19 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $275 · 2022: $398 · 2023: $332 · 2024: $780 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $626 · Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $626.26 |
| Food and Beverage | $614.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Photonicare INC | $646.67 | 2023-2024 | Otosight Middle Ear Scope |
| Bayer Healthcare Pharmaceuticals INC. | $308.13 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $253.35 | 2022-2024 | Rexulti |
| Novo Nordisk INC | $205.59 | 2021-2022 | |
| Pfizer INC. | $74.81 | 2021-2024 | |
| Idorsia Pharmaceuticals US INC | $67.53 | 2022-2024 | Quviviq |
| Astrazeneca Pharmaceuticals Lp | $65.90 | 2023-2025 | Farxiga, Lokelma |
| Biohaven Pharmaceutical Holding Company Ltd. | $42.18 | 2022 | |
| Exact Sciences Corporation | $36.84 | 2025 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $34.53 | 2021 | |
| Eisai INC. | $30.74 | 2021 | |
| Ortho-Clinical Diagnostics, INC. | $25.28 | 2025 | Sofia |
| Xeris Pharmaceuticals, INC. | $20.68 | 2025 | Keveyis |
| Abbvie INC. | $19.97 | 2025 | |
| Urogen Pharma, INC. | $17.54 | 2024 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $16.89 | 2024 | Nuzyra |
| Vbi Vaccine (Delaware) INC. | $16.51 | 2022 | |
| Lilly USA, LLC | $15.62 | 2022 | |
| Glaxosmithkline, LLC. | $15.15 | 2023 | Trelegy Ellipta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.